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Mesenchymal stem cells (MSCs) are adult multipotent cells that give rise to various cell
types of the mesodermal germ layer. MSCs are of great interest in the field of regenerative
medicine and cancer therapy because of their unique ability to home to damaged and
cancerous tissue. These cells also regulate the immune response and contribute to
reparative processes in different pathological conditions, including musculoskeletal and
cardiovascular diseases. The use of MSCs for tissue repair was initially based on the
hypothesis that these cells home to and differentiate within the injured tissue into
specialized cells. However, it now appears that only a small proportion of transplanted
MSCs actually integrate and survive in host tissues. Thus, the predominant mechanism by
which MSCs participate in tissue repair seems to be related to their paracrine activity.
Indeed, MSCs provide the microenvironment with a multitude of trophic and survival
signals including growth factors and cytokines. Recent discoveries suggest that lipid
microvesicles released by MSCs may also be important in the physiological function of
these cells. Over the past few years the biological relevance of micro- and nano-vesicles
released by cells in intercellular communication has been established. Alongside the
conventional mediators of cell secretome, these sophisticated nanovesicles transfer
proteins, lipids and, most importantly, various forms of RNAs to neighboring cells,
thereby mediating a variety of biological responses. The physiological role of MSC-derived
vesicles (MSC-MVs) is currently not well understood. Nevertheless, encouraging results
indicate that MSC-MVs have similar protective and reparative properties as their cellular
counterparts in tissue repair and possibly anti-cancer therapy. Thus, MSC-MVs represent a
promising opportunity to develop novel cell-free therapy approaches that might overcome
the obstacles and risks associated with the use of native or engineered stem cells.
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THE THERAPEUTIC POTENTIAL OF MESENCHYMAL
STEM CELLS
Over the last decades, adult stem cells have been extensively
studied with regard to their potential implications in regenera-
tive medicine. The multipotent precursors of the bone marrow
stroma were the first adult stem cells to be identified (Till and
McCulloch, 1964; Friedenstein et al., 1970) and are still now a
focus of great interest because of their ability to home to damaged
sites, function in tissue repair and regeneration and modulate
the immune response. As a result of their self-renewal poten-
tial and of their ability to differentiate to various phenotypes of
the mesenchymal germ layer, these non-hematopoietic stromal
cells are currently referred to as mesenchymal stem cells (MSCs)
(Caplan, 1991).
In the bone marrow MSCs represent about the 0.01% of
the mononuclear cells and provide the structural and func-
tional support for hematopoietic stem cells (HSCs) in their
niche (Johnson and Dorshkind, 1986; Pittenger et al., 1999).
However, MSCs have been isolated from a variety of fetal and
adult tissues including placenta, umbilical cord blood, adipose
tissue (Lee et al., 2004), skeletal muscle, peripheral blood (Bosch
et al., 2000; Zvaifler et al., 2000), dental pulp, and, more
recently, endometrium and menstrual blood (Musina et al.,
2008). Among the various sources, adipose tissue is gaining more
and more interest because adipose-derived MSC are available in
large amounts from liposuction procedures and thus considered
major candidates for future regenerative medicine approaches
(Schreml et al., 2009).
MSC CHARACTERISTICS
The identification and the characterization of MSCs have been
widely discussed elsewhere (Dominici et al., 2006). The absence
of known specific MSC-restricted markers and the observation
that the morphology of these cells can vary from spindle to
trapezoid shape depending on culture conditions and passage,
render it challenging to univocally identify MSCs. For this reason,
the International Society for Cellular Therapy (ISCT) established
minimal requirements to designate MSCs, i.e., (1) plastic adher-
ence, (2) expression of CD73, CD90 and CD105, and negativity
for various hematopoietic markers, and (3) ability to differentiate
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into mesenchymal cell types including adipocytes, chondrocytes
and osteoblasts (Dominici et al., 2006).
In spite of these efforts, there is still a high need to further
characterize the biology of these adult stem cells. In particu-
lar, plastic adherence does not appear an essential characteristic
of MSCs, as conceived previously. Recent studies from multiple
laboratories have shown the existence of non-adherentMSC (NA-
MSC) subpopulations that display the samemultipotent potential
of adherent MSCs. Moreover, the non-adherent MSCs present
the same ability to migrate to damaged tissues in vivo as adher-
ent MSCs and also function in tissue repair and regeneration
(Leonardi et al., 2009; Zhang et al., 2009).
The surface antigen pattern is also an aspect of MSC charac-
terization to be carefully considered because the expression of
markers changes depending on the surrounding environment,
during culture and upon exogenous stimuli (Dominici et al.,
2006).
Finally, concerning the multipotent potential of these
cells, the existence of a subpopulation within bone marrow-
derived MSCs capable of differentiating not only into the
same mesodermal-lineage, but also into other lineages of the
ectodermal and endodermal germ layers has been proposed, but
is still strongly debated (Dezawa et al., 2004, 2005; Trzaska et al.,
2007; Snykers et al., 2011).
The increasing interest around adult MSCs is further triggered
by at least two additional characteristics: the immunoregulatory
properties of these cells and their homing ability and specificity
(Figure 1).
IMMUNOREGULATORY PROPERTIES OF MSCs
One of the best-described functional properties of MSCs in vivo
is their potent effect on the immune system. Indeed, it is well-
known that MSCs have the capacity to suppress the immune
response (Jiang et al., 2005; Corcione et al., 2006; Casiraghi et al.,
2008; Jarvinen et al., 2008; Sheng et al., 2008). However, it has also
been demonstrated that they can function as antigen presenting
cells (Chan et al., 2006; Stagg et al., 2006).
The latter property of MSCs has been exploited successfully in
a therapeutic setting to overcome graft versus host disease after
haemopoietic-stem-cell transplantation (Le Blanc et al., 2008). In
addition, MSCs have been used to limit inflammation in Crohn’s
diseases (Garcia-Olmo et al., 2005), and to reduce autoimmune
side-effects following engraftment (Christopeit et al., 2008).
Numerous characteristics contribute to the immunosuppressive
FIGURE 1 | Mesenchymal stem cell properties and relevance for
therapeutic applications. Mesenchymal stem cells (MSCs) can be isolated
from different sources, in particular from bone marrow and adipose tissues,
and can differentiate into various cell types of the mesodermal germ layer. The
possibility that these adult stem cells can differentiate in cells of the other
germ layers is not excluded and is still debated. Two main properties make
MSCs good candidates for therapeutic applications. First, their ability to enter
the blood circulation and home to sites of inflammation, i.e., damaged and
cancerous tissues, where MSCs can release a multitude of trophic factors.
Second, MSCs have the ability to suppress the immune system via different
mechanism. While the latter property, together with the tropism for injured
sites, can be exploited in the field of regenerative medicine, the homing of
MSCs, engineered to carry anti-proliferative or pro-apoptotic signals, to cancer
may be important for the development of anticancer therapy approaches.
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effect of MSCs. Besides being characterized by low expression of
Major Histocompatibility Complex class II (MHCII) and costim-
ulatory molecules (B7-1 and B7-2), they interfere with various
pathways of the immune response by means of cell-to-cell inter-
actions and secretion of soluble factors, including members of
the transforming growth factor-β family, interleukins 6 and 10,
matrix metalloproteinases (MMPs), nitric oxide and indoleamine
2,3 deoxygenase (IDO). Different studies have reported the abil-
ity of MSCs to suppress T-cell proliferation, most likely via
Prostaglandin E2 (PGE2) production (Jarvinen et al., 2008), to
induce the T regulatory cells (Casiraghi et al., 2008), and to
express co-inhibitory molecules as B7-H1 on their surface upon
IFN-γ treatment (Sheng et al., 2008).Moreover,MSCs can impair
maturation and function of dendritic cells and inhibit the prolif-
eration, the differentiation and the chemotaxis of B-cells in vitro
(Aggarwal and Pittenger, 2005; Beyth et al., 2005; Jiang et al.,
2005; Corcione et al., 2006).
The immune-stimulating properties of these adult stem cells
have been less investigated and seem to depend on the produc-
tion of pro-inflammatory cytokines (Rasmusson et al., 2007). The
dual immunoregulatory function of MSCs has been proposed to
be cell dose-dependent, since high numbers of MSCs suppress
whereas very low numbers seem to stimulate lymphocyte prolifer-
ation (Le Blanc et al., 2003). This latter observation has important
implications in the use of MSCs as cell-therapeutics, as the cell
dose is critical for the in vivo function and may rely on factors
that are not well-understood, thereby limiting widespread use in
the clinic.
HOMING OF MSCs
An important distinguishing feature of MSCs compared to most
other cell-types is that MSCs retain the ability to migrate to
differentiated tissues. A number of telling studies have clearly
demonstrated that when MSCs are systemically or locally admin-
istered, they selectively home to sites of injury and cancer (Ortiz
et al., 2003; Rojas et al., 2005; Kidd et al., 2009). In pathological
conditions an increase of circulating MSCs can be observed, sug-
gesting the existence of a reservoir of mesenchymal cells that are
mobilized in response to injury to target the damaged site and aid
in tissue repair (Alm et al., 2010; Deng et al., 2011).
Why MSCs specifically home to these sites and what dam-
aged and cancerous tissues have in common that attract MSCs are
still open questions, but inflammation is most likely the respon-
sible denominator. The high concentration of inflammatory
chemokines released after tissue damage can indeed control the
migration ofMSCs, which express receptors for a number of grow
factors including PDGF and IGF-1, and chemokines receptors, as
CCR2, CCR3, CCR4, and CCL5 (Ponte et al., 2007). On the other
hand, strong connections exist between tissue injury, chronic
inflammation and cancer, as first described by Mina Bissell’s
group (Dolberg et al., 1985), so that tumors have been defined
“wounds that do not heal” (Dvorak, 1986), where inflammatory
cytokines and chemokines are produced and can driveMSC hom-
ing (Birnbaum et al., 2007; Dwyer et al., 2007;Menon et al., 2007).
The current knowledge about the mechanisms driving MSC
migration and homing comes from studies on leukocytes
(Butcher, 1991) and HSCs (Voermans et al., 1999). The
initial adhesive interactions between circulating leukocytes and
endothelial cells, called “rolling contacts,” are mediated by
selectins (Lawrence and Springer, 1991). Next, the activation
of integrin adhesiveness by chemokines determines the forma-
tion of more firm contacts that ultimately lead to extrava-
sation (Lewinsohn et al., 1987). Bone marrow-derived MSCs
express various integrins on their surface, among which inte-
grin α4/β1, which mediates cell-cell and cell-extracellular matrix
interactions by binding to vascular cell adhesion molecule
(VCAM)-1 and to the V-region of fibronectin, respectively. In
damaged tissues fibronectin is deposed together with fibrin at
the injured sites to stop the bleeding. The provisional matrix
is then remodeled by macrophages and fibroblasts, determin-
ing an increase in V region-exposing fibronectin, which, in
turn, allows MSCs to adhere and transmigrate into the extra-
cellular matrix (Valenick et al., 2005). Among the chemotac-
tic chemokines involved in MSC homing, stromal cell-derived
factor 1 (SDF-1) seems to play an important role. Although
only low levels of the SDF-1 receptor, CXCR4, are present on
the surface of MSCs, high intracellular levels of the recep-
tor have been detected and seem to function as a reservoir.
Indeed intracellular CXCR4 can be translocated to the membrane
upon chemokine stimulation, thus contributing to the migra-
tion of MSCs (Wang et al., 2001; Wynn et al., 2004). Moreover,
MSCs are able to secrete different metalloproteinases, including
MMP-2 and MT1-MMP, which degrade the extracellular matrix
barriers and allow extravasation and subendothelial migration
(Ries et al., 2007).
The precise mechanisms drivingMSC homing are still unclear,
but represent a very attractive subject of investigation because of
their implications in the therapeutic applications of these cells, as
both reparative effectors and vectors of specific signals.
MSCs IN REGENERATIVE MEDICINE
The unique characteristics of MSCs, such as their multipotency,
immunological properties, homing and effects on tissue repair,
raised expectations on the possibility to exploit these cells for
therapeutic approaches. Indeed, MSCs are readily isolated from
bone marrow and fat tissue (Lee et al., 2004), and can be admin-
istered to patients in an autologous manner, thus preventing
rejection by the immune system.
MSCs have been extensively studied and already clinically
tested for their role in bone repair and regeneration. Allogeneic
MSCs have been used for the treatment of bone disorders as
osteogenesis imperfecta (Horwitz et al., 2002; Le Blanc et al.,
2005; Otsuru et al., 2012). For bone tissue engineering applica-
tions, these cells are used in combination with “scaffolds” that
are designed to allow cell adhesion, survival and growth and that
are even functionalized to provide cells with pro-osteogenic stim-
uli (Warnke et al., 2004; Marcacci et al., 2007). The advantage
of using mesenchymal osteogenic precursors relies not only on
the ability of these cells to differentiate into osteoblasts, but also
on their capacity to provide trophic signals as growth factors
and cytokines to the damaged tissues, thereby accelerating the
regeneration process (Ciapetti et al., 2012).
Apart from bone-repair MSCs are also used to treat cardio-
vascular diseases. In particular acute myocardial infarction has
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been an important area of study to exploit MSC-based thera-
pies. Cell death due to ischemia leads to decreased contractility
of the heart. The general lack of an effective intrinsic mechanism
to repair such damage prompted researchers to investigate both
in vitro and in vivo the ability of MSCs to differentiate into car-
diomyocytes (Toma et al., 2002; Wang et al., 2006). However, as
mentioned before, there is currently no clear consensus if MSCs
have the ability to differentiate into cardiomyocytes and, if so, by
what signals. Experiments conducted by intravenously injecting
MSCs in rodents showed that the majority of cells are “trapped”
in the lungs (Schrepfer et al., 2007; Fischer et al., 2009). Moreover,
only a small percentage of MSCs administered in swines using
different delivery approaches is retained in the heart 2 weeks
after transplantation (Freyman et al., 2006). For these reasons, it
is believed that the positive effects of MSCs on damaged heart,
may not be solely due to their ability to differentiate into car-
diomyocytes. Instead, the release of trophic factors together with
the suppression of inflammation may also be responsible for the
healing effects of MSCs.
MSCs are also used for the treatment of neuronal injury
and neurodegenerative diseases such as Alzheimer’s, Parkinson’s
and Huntington’s diseases. In this case, the reparative poten-
tial could depend on the ability of MSCs to locally secrete high
amounts of brain-derived neurotrophic factor (BDNF), nerve
growth factor (NGF), vascular endothelial growth factor (VEGF)
and hepatocyte growth factor (HGF), indeed in vitro experi-
ments have shown that the expression of these factors increases
when MSCs are exposed to injured brain extracts (Chen et al.,
2002). Moreover, the ability of MSCs to modulate the immune
response might be crucial for neurodegenerative diseases char-
acterized by chronic inflammation (Lee et al., 2010). However,
different studies have also suggested the trans-differentiation
of bone marrow-derived MSCs into neuronal-like cells under
specific induction in vitro (Tondreau et al., 2008; Trzaska and
Rameshwar, 2011).
Finally, MSCs are able to reverse acute kidney injury in mouse
models. Also in this case the precise mechanisms by which MSCs
protect from tissue damage is not understood. While initial stud-
ies demonstrated that trans-differentiation of the administered
MSCs into tubular epithelium cells was responsible for the struc-
tural and functional repair of the kidney (Morigi et al., 2004),
following experimental evidences revealed that only 2.0–2.5% of
MSCs were actually engrafted (Herrera et al., 2007). Therefore,
as suggested by additional studies in rodents, the release of fac-
tors that can regulate the immune response and have trophic,
pro-angiogenic and mitogenic activities is the most accepted
mechanism of action of MSCs in kidney repair (Tögel et al., 2005;
Semedo et al., 2009).
MSCs IN ANTICANCER THERAPY
While the potential of using MSCs in regerative medicine is
releatively well-established, the use of MSCs in anticancer ther-
apy is receiving increasing attention. Because MSCs have a clear
capacity to home specifically to tumor sites in humans, they
could be used as specialized delivery vehicles for targeted anti-
cancer drugs or gene-therapy (Kidd et al., 2009, 2010; Loebinger
et al., 2009; Sasportas et al., 2009; Yang et al., 2009). Nonetheless,
this putative approach raises many (safety) questions because,
although MSCs have intrinsic anti-tumorigenic activities, they
also hold pro-tumorigenic properties, as suppressing the immune
response and expressing growth factors and pro-angiogenic
molecules that can aid in the formation of cancer stem cell niches
(Roorda et al., 2009). Grisendi et al. already designed a novel
cancer therapy strategy relying on the use of adipose-derived
mesenchymal progenitors (AD-MSCs) as cellular vectors of a
pro-apoptotic signal, i.e., tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL). When injected intravenously or sub-
cutaneously into mice, TRAIL-transduced AD-MSCs were able
to localize into tumors and mediate tumor cell apoptosis with-
out apparent toxicities to normal tissues (Grisendi et al., 2010).
Whether this strategy may also be suitable to eradicate human
tumors awaits to be studied.
LIMITATIONS OF STEM CELL THERAPY
The use of stem cells for the therapy of human diseases raised
several concerns in the past decade that proved a challenging
objective to overcome. The result of the interaction between adult
stem cells and target microenvironment needs to be further inves-
tigated before we can rule out potential risks for human health
and obtain effective approaches for regenerative medicine.
Some of the challenges concerning transplanted MSCs are
immune-mediated rejection, senescence-induced genetic insta-
bility or loss of function, and limited cell survival (Lim et al.,
2011). Besides these issues, the major problem in using MSCs for
clinical applications is the possibility of malignant transforma-
tion. The production of a sufficient amount of MSCs for clinical
use requires a consistent in vitro expansion, which can lead to
spontaneous transformation of the cells (Rubio et al., 2008).
The exact mechanisms of MSC transformation are not com-
pletely understood, but c-myc upregulation, p-16 repression and
increased telomerase activity seem to be involved. Furthermore,
genetic manipulations of MSCs for the treatment of different dis-
eases can per se increase the oncogenic potential of the cells, either
because the transgene may be tumorigenic or because it might
cause disruptions in the genome. MSCs have been found in a
number of tumors including gastric adenocarcinoma (Xu et al.,
2011), lipoma (Lin et al., 2007) and osteosarcoma (Brune et al.,
2011), strongly suggesting their involvement in tumor develop-
ment, and, importantly, various studies indicate these cells as
potential sources of tumor associated fibroblasts (TAFs) (Kidd
et al., 2012).
In the light of these observations, the choice of translating the
potential of MSCs to the clinic should be cautiously considered.
MSC RELEASED VESICLES AS A NOVEL APPROACH OF
CELL-FREE THERAPY
In spite of the multipotent and self-renewal potential of MSCs
and beyond the somewhat controversial ability of these cells to
trans-differentiate into lineages of other germ layers, MCS have
clear beneficial effects in the reparative processes of injured tis-
sues. Experimental studies showed that only a small proportion
of MSCs, locally or systemically administered, will actually be
incorporated into injured tissues (Rosario et al., 1997; Li et al.,
2008), indicating that the beneficial effects in tissue repair and
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regeneration is more likely indirect and depends on the paracrine
activity of MSCs and not on their engraftment.
This intriguing hypothesis opens novel therapeutic
perspectives aimed at the development of cell-free strategies
based on the use of MSC secretome as a safe and potentially more
advantageous alternative to cell-therapy approaches. While the
soluble secretome of MSCs is partly characterized (Parekkadan
et al., 2007; Lee et al., 2010; Roche et al., 2012), it seems unlikely
that specific cytokines and growth factors alone give MSCs their
remarkable healing abilities.
EXOSOMES AND MICROVESICLES
Besides the long-time notion of growth factors and cytokines
being an important part of the cellular secretome, it now appears
that most, if not all cells, secrete large amounts of micro- and
nano-vesicles, either constitutively or upon activation signals. The
biochemical composition, the complex biogenesis of these vesicles
and, in particular, their physiological role have only partially been
unraveled. Yet, their potential as mediators of cell communica-
tion has not gone unnoticed, since these vesicles have remarkable
features, including the ability to transfer proteins and functional
genetic material such as RNA to other cells (Ratajczak et al., 2006;
Valadi et al., 2007; Skog et al., 2008; Pegtel et al., 2010).
In particular exosomes have received much attention as these
are a subclass of (nano)vesicles (50–100 nm) that are derived
from specialized intracellular compartments known as late endo-
somes or Multi-vesicular bodies (MVBs). Many other types of
vesicles exist that presumably derive from the plasma membrane
and consensus has been reached to collectively name these extra-
cellular membrane vesicles. Exosomes are released from most
cells constitutively, but following activation their release is sig-
nificantly increased. They were first implicated in reticulocyte
maturation and later shown to have an important role in immune
responses. More recently exosomes have been found in different
biological fluids such as urine, plasma, malignant and pleu-
ral effusions of ascites and synovial fluid, and, because of their
specific content, have been proposed as suitable biomarkers of
different diseases (Skog et al., 2008; Nilsson et al., 2009). The
biogenesis of exosomes involves the formation of intraluminal
vesicles (ILV) by inward budding of the limiting membrane of
MVBs. It is presumed, although many molecular details are lack-
ing, that MVBs fuse with the plasma membrane to release the
ILVs as exosomes (Figure 2). Once secreted exosomes can either
be taken up by target cells localized in proximity of the cell of
origin or travel to more distant sites through the blood and
possibly other biological fluids. Théry et al. (2006) provided a
detailed description of the most recognized procedures to iso-
late and characterize exosomes from cell supernatant and bodily
fluids. The development and use of standardized protocols is
critical because other kinds of vesicles as well as membrane frag-
ments are normally present in the starting material and can
contaminate exosome preparations. Mechanistically, exosomes,
but also other types of microvesicles, can operate in a multi-
tude of ways since they can be considered as complex vectors
that can hold essentially all known biological molecules and
likely the solutes that are present in the parental cells. These
molecules include, but are not restricted to, proteins (both
FIGURE 2 | Schematic representation of exosome biogenesis.
Intraluminal vesicles (ILVs) are generated by the inward budding of the
limiting membrane of a subgroup of late endosomes called multivesicular
bodies (MVBs). MVBs can be directed towards the cell periphery and, after
fusion with the plasma membrane, release their content in the extracellular
space. Secreted ILVs, now called “exosomes,” are then taken up by target
cells (A). Electron microscopy picture of exosomes isolated by differential
ultracentrifugation (B).
ubiquitous and cell-specific), mRNAs, microRNAs (miRNAs) and
lipid molecules.
Given the multiplicity of signals carried by these vesicles
through the horizontal transfer of functional RNAs and pro-
teins, their implication in various diseases and especially in can-
cer is being intensively investigated. It is becoming more and
more evident that cancer cells exploit exosome-mediated signal-
ing to modify their microenvironment, but also to exert systemic
functions. Indeed exosomes can promote the formation of pre-
metastatic niches, thereby optimising the conditions for tumor
spreading (Hood et al., 2011). Moreover, the amount and the
content of exosomes consistently vary based on the microenvi-
ronmental conditions, and particularly when cells are subjected
to stress factors (Parolini et al., 2009; Hedlund et al., 2011;
Lv et al., 2012). For instance, the acidic extracellular pH asso-
ciated with the aggressiveness and chemoresistance of various
solid tumors (Simon et al., 1993; Mahoney et al., 2003; Nishisho
et al., 2011) is able to increase exosome release and uptake
(Parolini et al., 2009).
On the other hand, the sophisticated make up of exosomes,
which strongly suggests an important role in cell-cell commu-
nication, opens novel perspectives in exploiting these vesicles in
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therapeutic settings. Exosomes might be isolated from cells that
hold promising therapeutic applications, as MSCs in regenera-
tive medicine, and systemically or locally administered to mimic
the effect of the parental cell. Whether MSC-derived exosomes
retain the homing properties of the cells of origin is still largely
unknown and is an important question to be answered, although
in vivo studies have shown beneficial effects of intravenously
injected exosomes in tissue repair. Moreover, exosomes can be
used as targeted delivery vehicles of therapeutic miRNAs. Alvarez-
Erviti et al. (2011) succeeded in delivering functional siRNA to
the mouse brain by systemically injecting targeted exosomes. To
confer tissue-specificity to exosomes the authors engineered low
immunogenic cells to express an exosomal membrane protein,
Lamp2b, fused to the neuron-specific RVG peptide. Exosomes
were then isolated and loaded with exogenous siRNAs by elec-
troporation. Considering the reparative, immune suppressive and
homing properties of MSCs, the use of exosomes derived from
these cells modified to express high levels of specific miRNAs
could also be considered, once ascertained that the miRNAs of
interest are actually enriched in the exosomal compartment. In
case the tropism of exosomes would not reflect that of MSCs or
if different targeting would be required, exosomes bearing tissue-
specific receptor on their surface could be engineered (Alvarez-
Erviti et al., 2011), or local administration might be considered
(Figure 3).
CHARACTERIZATION OF MSC-RELEASED VESICLES
Despite the interest raised by MSC-derived microvesicles for their
potential role in physiological and pathological conditions, and
for their possible applications in the treatment of various diseases,
only few studies have been conducted on the (specific) RNA and
protein content of these vesicles.
The presence of selected miRNAs within MSC-derived
microvesicles has been proposed by Collino et al. (2010). In
these studies a comparative miRNA profiling was performed
with arrays using bone marrow and tissue specific (liver) MSCs
and their respective microvesicles. The authors found that some
miRNAs were present both in microvesicles and in the cells of
origin. However, some miRNAs appeared to have been selec-
tively sorted into the MVs, as these were not detectable in the
cells, while, on the contrary, others were present in the cells
but not in the MVs. These observations support the existence
of a mechanism that controls the sorting of miRNAs in MSC
vesicles. Nevertheless, without accurate quantitation by either
deep-sequencing techniques and/or quantitative RT-PCR in com-
bination with functional experiments, the biological relevance
of these findings remain unclear. The only way to explain that
miRNAs are present in exosomes and not in the producing cells
is that the mature RNA species are rapidly secreted, having no
chance to accumulate within the cytoplasm with the risk of being
degraded. Specific miRNAs might be produced by these cells
only for the purpose of cell–cell communication, without ever
reaching a critical level in the cell of origin to exert a func-
tion, being repressing the translation of particular target mRNAs.
Although this is possible in theory, no experimental data is
available. In contrast, the sorting of specific signaling molecules
(proteins) into exosomes does seem to have a clear effect on the
FIGURE 3 | Proposed model for therapeutic applications of
MSC-derived exosomes. MSC-derived exosomes may be used instead of
MSCs in regenerative medicine and anticancer therapy, since they seem to
hold the beneficial properties of the parental cells. MSC-derived exosomes
might retain the homing ability displayed by MSCs towards sites of
inflammation and function in tissue repair, also by modulating the immune
response. Concerning anticancer therapy, exosomes derived from
engineered MSCs might be used to mediate anti-proliferative or
pro-apoptotic effects. Moreover, whenever the tropism of exosomes would
not be retained, MSCs may be modified to confer specific targeting to
exosomes.
producing cells (Chairoungdua et al., 2010; Verweij et al., 2011)
and may also be of importance in vivo (Al-Nedawi et al., 2009;
Peinado et al., 2012). However, it does appear that microRNAs
may be specifically transported into cells for specialized functions
while the target cells seems to lack these microRNAs (Rader and
Parmacek, 2012).
Based on the Gene Ontology analysis, the predicted and
validated targets of the miRNAs detected in both MSCs and
MSC-MVs are related to development, cell survival and dif-
ferentiation, while some MSC MV-enriched miRNAs were
more associated with the regulation of the immune system.
Moreover, microvesicle-derived miRNAs transferred to recipient
cells were able to suppress specific targets, thus confirming the
functionality of these mediators in cell-to-cell communication
(Collino et al., 2010).
Besides the genetic content of MVs, the proteome may be
equally important. Only one study has been conducted so far
that characterized the protein composition of MSC-derived MVs
in more detail. By characterizing the content of bone marrow
MSC-derived MVs, Kim et al. identified 730 proteins, among
which mediators controlling self-renewal and differentiation.
Interestingly, their analysis revealed a number of surface markers
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such as PDGFRB, EGFR, and PLAUR, signaling molecules
of RAS-MAPK, RHO, and CDC42 pathways, cell adhesion
molecules and additional MSC antigens that support a possible
role for such vesicles in tissue repair (Kim et al., 2012). Based on
these results, it appears that MSC-MVs hold many of the char-
acteristics of the MSCs themselves, and may be important for
the function of these adult stem cells in vivo besides the classic
secreted factors.
MSC-RELEASED VESICLES IN REGENERATIVE MEDICINE AND CANCER
While the predominant role of MSC paracrine activity in tissue
repair has already been established, whether MSC-MVs also have
a role remains to be studied.
The protective paracrine activity of MSCs in kidney injury
fostered several studies into the potential contribution of MSC-
derived microvesicles in renal repair. Microvesicles released by
MSCs protect against renal injury in the mouse remnant kid-
ney model, support renal repair in ischemia/reperfusion-induced
acute kidney injury (AKI), and protect from lethal cisplatin-
induced AKI, most likely by inhibiting apoptosis of tubular
epithelial cells (Gatti et al., 2011; Bruno et al., 2012; He et al.,
2012).
In animal models of intervertebral disc (IVD) degeneration
MSCs have been demonstrated able to restore the normal disc
structure. Since IVD degeneration seems to depend on alterations
of nucleus pulposus (NP) cells, Strassburg et al. (2012) inves-
tigated the interactions between MSCs and degenerate NP cells
and found that the two cell types primarily communicate via
an extensive direct transfer of membrane components and via
microvesicles.
The potential use of MSC-MVs for the treatment of
cardiovascular diseases has recently been reviewed by Lai
et al. (2011). The authors previously demonstrated the ther-
apeutic activity of MVs isolated from embryonic stem cell-
derived MSCs (ESC-MSCs) in a mouse model of myocar-
dial ischemia/reperfusion (Lai et al., 2010). They suggest
that the secretion of protective exosomes is a general prop-
erty and perhaps a predominant function of MSCs, prob-
ably related to the supporting role of the stromal cells.
Considering the limitations and costs related to the use of
embryonic stem cells and the high amount of cells required
for MV production, the same group also generated MYC-
immortalized ESC-MSCs and demonstrated that MVs derived
from these cells still display their original cardioprotective activity
(Chen et al., 2011).
If the beneficial and protective effects of MSC-MVs in tissue
repair have been reported in different pathological conditions,
their use for cancer therapy needs careful consideration.
Bone marrow MSC-derived exosomes have been shown to
support tumor growth and angiogenesis in a mouse xenograft
model of gastric carcinoma, and the pro-angiogenic effect has
been ascribed to the increase of VEGF expression in tumor cells
(Zhu et al., 2012). This evidence is not completely unexpected
since MSCs have been reported to have various tumor promot-
ing functions (Roorda et al., 2009), and highlights once more
that it is mandatory to be cautious when evaluating the risks
related to the use of engineered MSCs or MSC-derived exosomes
in anticancer therapy. Finally, Kyo Won Lee’s group demon-
strated that both breast and ovarian cancer cells (Cho et al.,
2011, 2012) can condition AD-MSCs to generate tumor associ-
ated myofibrobasts. It might be interesting to investigate whether,
in turn, MSC-derivedmyofibroblast-like cells, or pre-conditioned
MSCs exploit the same mechanism to further support tumor
development.
CONCLUDING REMARKS
While the use of MSCs in regenerative medicine and anti-cancer
treatment raised high expectations, concerns about safety and
tight regulations hampered their practical use in clinical settings.
However, the use of MSC-derived secretome and, in particular,
of the vesicles released by these cells may have many advantages
compared to a cell-based approach.
The increasing interest around this strategy of intercellular
crosstalk adopted by MSCs relies on the ability of these vesicles
to condition and reprogram the surrounding microenvironment,
thereby influencing a variety of biological responses, in particular
in injured tissues and cancer.
MVs function primarily in cell–cell communication, which
is, as discussed above, highly relevant in the biology of MSCs.
The significant contribution of MSC paracrine activity, rather
than their ability to differentiate, to the reparative process has
already been established. It will now be of importance to deci-
pher the exact role of MSC secretome and vesicles, since it is
likely that in parallel to soluble factors as growth factors and
cytokines, MVs strongly contribute to the paracrine effects of
these cells. Indeed MVs present a complex composition that mir-
rors that of the parental cells and seems to have similar properties
in vivo.
Therefore, the use of MSC secretome-derived vesicles rep-
resents an interesting alternative for tissue repair that might
overcome the limitations and risks associated to cell-therapy
approaches. Concerning the potential applications for cancer
therapy, exosomes released by opportunely engineered MSCsmay
still retain the ability to home to tumor site and, at the same
time, mediate anti-proliferative or pro-apoptotic effects, relieving
the concerns related to the genetic manipulation of stem cells for
cell-therapy.
Evidently, crucial questions need to be answered before the
objective described above can be satisfactorily fulfilled. First, it is
necessary to verify to which extent MSCmicro- and nano-vesicles
contribute to the beneficial effects mediated byMSCs; second, the
content of these vesicles, in terms of proteins and, in particular,
small RNAs, needs to be thoroughly characterized; and, finally, it
is essential to uncover the effect of the genetic content of MSC-
MVs on recipients cells and determine which cellular pathways
may be affected.
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